Excelsior Biopharma Inc. (TPEX:6496)

Taiwan · Delayed Price · Currency is TWD

25.00

+0.10 (0.40%)

Aug 19, 2026, 1:30 PM CST

Excelsior Biopharma Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	936.92	898.26	861.91	771.56	671.76	1,338
Revenue Growth	7.59%	4.22%	11.71%	14.86%	-49.81%	-7.29%
Gross Profit	361.23	360.17	382.1	306.93	287.17	293.35
Operating Income	-199.67	-171.6	-80.97	-81.13	-29.29	-8.77
Net Income	-206.58	-183.17	-98.71	-91.01	-33.76	-15.65
Earnings Per Share	-4.46	-3.97	-2.14	-1.98	-0.74	-0.34
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Taiwan	861.23	797.79	722.07	637.96	1,297
China	35.99	56.6	48.4	33.62	40.96
Others	1.05	7.53	1.08	0.18	0.83
Total	898.26	861.91	771.56	671.76	1,338

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	141.1	185.34	251.53	589.92	1,106	1,103
Total Debt	524.98	511.31	410.59	354.22	351.24	364.63
Net Cash (Debt)	-383.88	-325.98	-159.07	235.7	755.23	738.13
Net Cash Growth	-	-	-	-68.79%	2.32%	-5.08%
Net Cash Per Share	-8.29	-7.06	-3.45	5.13	16.47	15.87

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-147.79	-138.72	-99.8	-134.75	5.49	55.82
Capital Expenditures	-14.6	-36.95	-257.15	-35.66	-7.78	-2.88
Free Cash Flow	-162.38	-175.67	-356.95	-170.41	-2.3	52.95
Free Cash Flow Growth	-	-	-	-	-	-89.60%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	38.55%	40.10%	44.33%	39.78%	42.75%	21.92%
Operating Margin	-21.31%	-19.10%	-9.40%	-10.51%	-4.36%	-0.66%
Pretax Margin	-20.80%	-19.19%	-10.14%	-10.62%	-3.87%	-0.75%
Profit Margin	-22.05%	-20.39%	-11.45%	-11.80%	-5.03%	-1.17%
FCF Margin	-17.33%	-19.56%	-41.41%	-22.09%	-0.34%	3.96%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 19, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	-	10.56	10.56	10.56	10.56	10.56
P/FCF Ratio	-	-	-	-	-	25.75
PS Ratio	1.24	1.52	1.63	1.76	1.93	1.02